Premium
Salivary side effects after radioiodine treatment for differentiated papillary thyroid carcinoma: Long‐term study
Author(s) -
Le Roux MarcKevin,
Graillon Nicolas,
Guyot Laurent,
Taieb David,
Galli Philippe,
GodioRaboutet Yves,
Chossegros Cyrille,
Foletti JeanMarc
Publication year - 2020
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.26359
Subject(s) - medicine , radioiodine therapy , thyroid carcinoma , side effect (computer science) , thyroid , papillary carcinoma , gastroenterology , surgery , computer science , programming language
Abstract Background Although many studies focus on short‐term side effects of radioiodine therapy, almost none studied long‐term side effects. We assessed radioiodine long‐term salivary side effects after radioiodine treatment for differentiated papillary thyroid carcinoma and compared it to short‐term morbidity within the same population. Methods A standardized self‐administrated questionnaire was submitted in 2019 by patients treated with radioiodine between January 2011 and December 2012. These patients had already answered the same questionnaire 6 years before. Results Our study showed a significant reduction for salivary side effects: discomfort in submandibular or parotid area, swelling, pain, a bad or salty taste in the mouth, allowing to get back to a “normal” diet. Conclusions Our study suggests that a significant rate of patients will recover from I 131 therapy salivary side effects. As almost 30% of these remissions happened during our late stage follow‐up, we highlight the necessity of a long‐term follow‐up in these patients.